TA1-SEPSIS-CN-OLE — design and population
Design, allocation, arms and the population enrolled.
Institute-constructed programme record. This document is not a report of a published trial. It is a record the Institute has constructed to represent an instalment, sub-study or extension of a real development programme, published in order to carry a methodological point that the parent trial report does not address. No effect estimate on this page is attributable to any publication, and its reference-list entry carries a programme-record label rather than a citation. The policy governing these records was settled through a public comment period.
§2Design and population
§2.1Design and allocation
- Design class
- Single-arm open-label study
- Masking
- None
- Arms
- 1
- Allocation
- Single arm; no randomisation
- Endpoint adjudication
- Not applicable to the primary endpoint of this design
- Data monitoring
- As specified in the protocol
§2.2Arms
Table 2. Randomised arms. Illustrative: arm-level allocations are reconstructed by the Institute from the design class and the randomised total where the published report does not state them.
| Arm | Allocated | Share | Description |
|---|---|---|---|
| Thymosin alpha-1 | — | — | Open-label active treatment; no randomised comparator |
| The randomised total is not recorded by the Institute and arm-level figures are therefore not presented. | |||
§2.3Population
Indication. Immune modulation and adjunctive immunotherapy
Pharmacological modification of innate or adaptive immune function, assessed by cell counts, functional assays and clinical infection or oncological endpoints.
Geographic footprint. United States · Sweden · Spain · Israel.
§2.4Eligibility as the Institute reads it
- Included. Pharmacological modification of innate or adaptive immune function, assessed by cell counts, functional assays and clinical infection or oncological endpoints.
- Excluded. Participants for whom the intervention is contraindicated, including known hypersensitivity. Exclusion criteria narrow the population to which the estimate applies and are the principal source of indirectness where a trial estimate is applied to ordinary practice.